Guidance around complete revascularization and intracoronary imaging is strengthened, and Impella gets a recommendation.
The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.
The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.
The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.
Clyde Yancy talks to Sharonne Hayes and Robert Harrington about the barriers that have historically hindered diagnosing heart ...
A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.
There’s no scientific evidence to support anecdotal claims—on social media or elsewhere—of a bump, Jonathan Drezner says.
A patient who, despite risk factors or comorbidities, can get on a treadmill faces low mortality risk. But the reverse is ...
The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.
This month: smelling skills predict stroke risk, insights from LGBTQ+ clinicians, BP screening in public spaces, and more.
The multisociety collaboration moves the focus from procedures to a continuum of care from diagnosis to any treatment ...
Finding the cause of angina in patients without obstructed coronaries can reassure patients and lead to tailored therapy.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果